US · ALLO · BIOTECHNOLOGY
Allogene Therapeutics, Inc. (ALLO) intrinsic value and stock valuation
$0.63as of 2026-11-21 · Mkt cap 673.05M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Allogene Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values ALLO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALLO’s statements →
Allogene Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Achieve Life Sciences, Inc. (ACHV) $6.78
- Kyverna Therapeutics, Inc. (KYTX) $4.26
- Cabaletta Bio, Inc. (CABA) $0.94
- Editas Medicine, Inc. (EDIT) $1.64
- Atea Pharmaceuticals, Inc. (AVIR) $3.96
- Vanda Pharmaceuticals Inc. (VNDA) $3.45
- Voyager Therapeutics, Inc. (VYGR) $1.53
- Caribou Biosciences, Inc. (CRBU) $0.28
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $20K | $100K | $160K | $114.1M |
| Operating income | -$-206.93M | -$-273.2M | -$-327.74M | -$-335.54M | -$-180.19M |
| Net income | -$-190.89M | -$-257.59M | -$-327.26M | -$-340.41M | -$-182.05M |
| EPSd | -$-865.24K | -$-1.32M | -$-2.09M | -$-2.38M | -$-1.34M |
| Operating cash flow | -$-149.25M | -$-200.3M | -$-237.73M | -$-220.52M | -$-184.81M |
| Capital expenditure | -$-390K | -$-690K | -$-1.52M | -$-5.19M | -$-21.45M |
| Free cash flow | -$-149.63M | -$-200.99M | -$-239.25M | -$-225.71M | -$-206.26M |
| Total assets | $415.9M | $548.7M | $642.8M | $821.6M | $1.05B |
| Total debt | $83.3M | $90.8M | $95.1M | $101.1M | $73.1M |
| Net debt | $31.6M | $15.5M | $12M | $39.2M | -$-100.19M |
| Total equity | $292.5M | $422.2M | $512.2M | $666.9M | $925.2M |
| Cash and short-term investments | $250.2M | $292.5M | $448.7M | $517.3M | $457.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $20K | $100K | $160K | $114.1M |
| Cost of revenue | $12.4M | $0.00 | $0.00 | $14.3M | $0.00 |
| Gross profit | -$-12.36M | $20K | $100K | -$-14.14M | $114.1M |
| Research and development expenses | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M |
| Selling, general and administrative expenses | $56.8M | $65.2M | $71.7M | $79.3M | $74.1M |
| Other expenses | -$-12.36M | $15.7M | $13.2M | -$-14.29M | $0.00 |
| Operating expenses | $194.6M | $273.2M | $327.8M | $321.4M | $294.3M |
| Cost and expenses | $206.9M | $273.2M | $327.8M | $335.7M | $294.3M |
| Interest income | $19.3M | $20.2M | $18.3M | $4.57M | $1.71M |
| Interest expense | $1.07M | $180K | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $12.4M | $13.6M | $14.2M | $14.3M | $10.5M |
| Ebitda | -$-177.45M | -$-243.33M | -$-313.07M | -$-326.12M | -$-171.6M |
| Operating income | -$-206.93M | -$-273.2M | -$-327.74M | -$-335.54M | -$-180.19M |
| Total other income/expenses, net | $16.1M | $16.1M | $470K | -$-4.88M | -$-1.86M |
| Income before tax | -$-190.89M | -$-257.15M | -$-327.26M | -$-340.41M | -$-182.05M |
| Income tax expense | $0.00 | $440K | $0.00 | $0.00 | $0.00 |
| Net income | -$-190.89M | -$-257.59M | -$-327.26M | -$-340.41M | -$-182.05M |
| Weighted average shares outstanding | $220.6M | $194.8M | $156.9M | $143.2M | $135.8M |
| Weighted average diluted shares outstanding | $220.6M | $194.8M | $156.9M | $143.2M | $135.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $250.2M | $292.5M | $448.7M | $517.3M | $457.3M |
| Net receivables | $1.5M | $1.9M | $1.7M | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $257.8M | $303.4M | $459.1M | $528.8M | $471.3M |
| Property, plant and equipment, net | $112.7M | $131.3M | $163.2M | $196.4M | $181M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $8.04M | $80.7M | $3.65M | $76.5M | $382.4M |
| Total non-current assets | $158.2M | $245.3M | $183.7M | $292.8M | $579.5M |
| Total assets | $415.9M | $548.7M | $642.8M | $821.6M | $1.05B |
| Accounts payable | $4.27M | $5.39M | $5.9M | $13.9M | $10.3M |
| Short-term debt | $8.21M | $7.51M | $6.78M | $6M | $3.2M |
| Deferred revenue | $0.00 | $0.00 | $90K | $100K | $160K |
| Total current liabilities | $32.5M | $35.5M | $37.1M | $53.7M | $47.9M |
| Long-term debt | $75.1M | $83.3M | $88.4M | $95.1M | $69.9M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $90.9M | $91M | $93.5M | $101M | $77.7M |
| Capital lease obligations | $83.3M | $90.8M | $95.1M | $101.1M | $73.1M |
| Total liabilities | $123.4M | $126.5M | $130.6M | $154.7M | $125.6M |
| Common stock | $230K | $210K | $170K | $140K | $140K |
| Retained earnings | -$-2.01B | -$-1.82B | -$-1.56B | -$-1.23B | -$-894.55M |
| Accumulated other comprehensive income (loss) | $270K | -$-90K | -$-950K | -$-9.93M | -$-2.57M |
| Total equity | $292.5M | $422.2M | $512.2M | $666.9M | $925.2M |
| Total investments | $206.6M | $297.9M | $369.2M | $531.9M | $666.4M |
| Total debt | $83.3M | $90.8M | $95.1M | $101.1M | $73.1M |
| Net debt | $31.6M | $15.5M | $12M | $39.2M | -$-100.19M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-190.89M | -$-257.59M | -$-327.26M | -$-332.63M | -$-257M |
| Depreciation and amortization | $12.4M | $13.6M | $14.2M | $14.3M | $10.5M |
| Stock-based compensation | $37.6M | $51.7M | $66M | $83.6M | $80.8M |
| Change in working capital | -$-10.88M | -$-24.8M | -$-15.3M | $3.71M | -$-32.09M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-1.23M | -$-500K | -$-7.5M | $4.87M | -$-770K |
| Net cash provided by operating activities | -$-149.25M | -$-200.3M | -$-237.73M | -$-220.52M | -$-184.81M |
| Investments in property, plant and equipment | -$-390K | -$-690K | -$-1.52M | -$-5.19M | -$-21.45M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-111.35M | -$-17.71M |
| Net cash used for investing activities | $95.6M | $75.7M | $163.3M | $106.2M | $163.7M |
| Common stock issued | $23.3M | $114.4M | $91.1M | $2.95M | $12M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $30.2M | $116.7M | $95.7M | $2.95M | $12M |
| Net change in cash | -$-23.53M | -$-7.94M | $21.3M | -$-111.41M | -$-9.19M |
| Cash at end of period | $62M | $85.5M | $93.5M | $72.2M | $183.6M |
| Operating cash flow | -$-149.25M | -$-200.3M | -$-237.73M | -$-220.52M | -$-184.81M |
| Capital expenditure | -$-390K | -$-690K | -$-1.52M | -$-5.19M | -$-21.45M |
| Free cash flow | -$-149.63M | -$-200.99M | -$-239.25M | -$-225.71M | -$-206.26M |
Line items
Line items
Line items
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
- CEO
- Zachary Roberts
- Employees
- 152
- Beta
- 0.46
Explore
Frequently asked questions
What is the intrinsic value of Allogene Therapeutics, Inc. (ALLO)?
InvestorsCraft does not currently publish an intrinsic value for ALLO. How the IC value is calculated.
Is ALLO undervalued?
InvestorsCraft does not publish an undervaluation signal for ALLO at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.